A Trial to Evaluate the Efficacy and Safety of YH12852 in Patients With Functional Dyspepsia
Primary Purpose
Functional Dyspepsia
Status
Terminated
Phase
Phase 2
Locations
Korea, Republic of
Study Type
Interventional
Intervention
YH12852 0.1 mg
YH12852 0.25 mg
YH12852 0.5 mg
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Functional Dyspepsia
Eligibility Criteria
Inclusion Criteria:
- Subjects must be willing and able to provide written informed consent.
- BMI of < 35 kg/m2
- Patients experiencing one or more of functional dyspepsia symptoms beginning at least 6 months prior according to Rome III criteria, with the symptom(s) evident over the last 3 months at the time of screening
- Patients with no evidence of organic lesions based on upper GI endoscopy, which could be the cause of dyspeptic symptoms
- Women of childbearing potential (WOCBP) must have a negative pregnancy test result at the screening visit and use an adequate method of contraception to avoid pregnancy throughout the study
Exclusion Criteria:
- Women who are pregnant or breastfeeding.
- Women with a positive pregnancy test result on enrollment or prior to investigational product administration.
- Subjects with a history of surgery that could affect gastrointestinal motility
- Subjects with inflammatory bowel disease
- Clinically significant chronic infection (eg. AIDS, etc), or significant medical or psychiatric illness.
- Serious cardiovascular disease (including QT prolongation defined as QTc interval ≥ 450msec) or respiratory disease
- History of alcohol or drug abuse within the previous one year.
- Subjects with mental illness (e.g. schizophrenia, dementia etc) that may render the inability to complete the study
- Physical and Laboratory Test Findings
- Administration of any other investigational product or participation in other clinical trials within 3 months prior to randomization.
Sites / Locations
- Samsung seoul hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Experimental
Experimental
Experimental
Placebo Comparator
Arm Label
YH12852 0.1 mg
YH12852 0.25 mg
YH12852 0.5 mg
Placebo
Arm Description
twice daily for 4 weeks
twice daily for 4 weeks
twice daily for 4 weeks
twice daily for 4 weeks
Outcomes
Primary Outcome Measures
Ratio of OTE (Overall Treatment Efficacy) responders
Secondary Outcome Measures
Ratio of OSS responders
Elimination rate for 8 functional dyspepsia symptoms
Change from basline in NDI QoL score
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02567578
Brief Title
A Trial to Evaluate the Efficacy and Safety of YH12852 in Patients With Functional Dyspepsia
Official Title
A Multicenter, Randomized, Double-blind, Placebo-controlled Dose-finding Phase 2 Trial to Evaluate the Efficacy and Safety of YH12852 in Patients With Functional Dyspepsia
Study Type
Interventional
2. Study Status
Record Verification Date
December 2021
Overall Recruitment Status
Terminated
Why Stopped
Technology transfer
Study Start Date
October 2015 (undefined)
Primary Completion Date
March 16, 2017 (Actual)
Study Completion Date
March 16, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Yuhan Corporation
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is a multicenter, randomized, double-blind, placebo-controlled dose-finding phase 2 trial to evaluate the efficacy and safety of YH12852 in patients with functional dyspepsia.
Detailed Description
Eligible subjects will be randomized into one of 4 groups; YH12852 0.1 mg, 0.25 mg, 0.5 mg, or placebo at the same ratio and will be administered investigational products orally, twice daily for 4 weeks and followed up for 2 weeks.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Functional Dyspepsia
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
12 (Actual)
8. Arms, Groups, and Interventions
Arm Title
YH12852 0.1 mg
Arm Type
Experimental
Arm Description
twice daily for 4 weeks
Arm Title
YH12852 0.25 mg
Arm Type
Experimental
Arm Description
twice daily for 4 weeks
Arm Title
YH12852 0.5 mg
Arm Type
Experimental
Arm Description
twice daily for 4 weeks
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
twice daily for 4 weeks
Intervention Type
Drug
Intervention Name(s)
YH12852 0.1 mg
Intervention Type
Drug
Intervention Name(s)
YH12852 0.25 mg
Intervention Type
Drug
Intervention Name(s)
YH12852 0.5 mg
Intervention Type
Drug
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Ratio of OTE (Overall Treatment Efficacy) responders
Time Frame
4 weeks
Secondary Outcome Measure Information:
Title
Ratio of OSS responders
Time Frame
4 weeks
Title
Elimination rate for 8 functional dyspepsia symptoms
Time Frame
4 weeks
Title
Change from basline in NDI QoL score
Time Frame
4 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
19 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subjects must be willing and able to provide written informed consent.
BMI of < 35 kg/m2
Patients experiencing one or more of functional dyspepsia symptoms beginning at least 6 months prior according to Rome III criteria, with the symptom(s) evident over the last 3 months at the time of screening
Patients with no evidence of organic lesions based on upper GI endoscopy, which could be the cause of dyspeptic symptoms
Women of childbearing potential (WOCBP) must have a negative pregnancy test result at the screening visit and use an adequate method of contraception to avoid pregnancy throughout the study
Exclusion Criteria:
Women who are pregnant or breastfeeding.
Women with a positive pregnancy test result on enrollment or prior to investigational product administration.
Subjects with a history of surgery that could affect gastrointestinal motility
Subjects with inflammatory bowel disease
Clinically significant chronic infection (eg. AIDS, etc), or significant medical or psychiatric illness.
Serious cardiovascular disease (including QT prolongation defined as QTc interval ≥ 450msec) or respiratory disease
History of alcohol or drug abuse within the previous one year.
Subjects with mental illness (e.g. schizophrenia, dementia etc) that may render the inability to complete the study
Physical and Laboratory Test Findings
Administration of any other investigational product or participation in other clinical trials within 3 months prior to randomization.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Poong Lyul Lee, MD, Ph.D
Organizational Affiliation
Samsung seoul hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Samsung seoul hospital
City
Seoul
Country
Korea, Republic of
12. IPD Sharing Statement
Learn more about this trial
A Trial to Evaluate the Efficacy and Safety of YH12852 in Patients With Functional Dyspepsia
We'll reach out to this number within 24 hrs